To determine whether
iptakalim inhibited endothelin-1(ET-1)-induced proliferation of human pulmonary arterial smooth muscle cells (PASMCs) through the activation of
ATP-sensitive
potassium (K(
ATP)) channel, the effect of
iptakalim on the ET-1-induced proliferation of human PASMCs was examined by [3H]
thymidine incorporation, staining with
propidium iodide and flow cytometry analyses, measurement of cytosolic free Ca2+ concentration ([Ca2+]cyt) and Western blot for the phosphorylation of
extracellular signal-regulated kinases 1 and 2 (ERK1/2) in vitro. The results showed that
iptakalim inhibited the ET-1-induced proliferation of human PASMCs, including [3H]
thymidine incorporation and the transition of cell cycle phase, and blocked the ET-1-induced transient raise of [Ca2+]cyt, and the ET-1-induced phosphorylation of ERK1/2 in the human PASMCs.
Iptakalim exerted a similar role as
pinacidil did in human PASMCs and both inhibited the [3H]
thymidine incorporation and the transition of cell cycle phase induced by ET-1 in the human PASMCs. Furthermore, we found that the inhibition of
iptakalim and
pinacidil on the ET-1-induced proliferation of human PASMCs was blocked by
glyburide, a selective K(
ATP) channel antagonist. These findings provide a strong evidence to support that
iptakalim acts as a specific K(
ATP) channel opener to antagonize the proliferating effect of ET-1 in the human PASMCs. This study provides further evidence that
iptakalim may serve as another candidate
drug to treat
pulmonary hypertension.